bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse.

  • Professor and Director - Center for Drug Abuse Research Translation
  • BNP
  • Psychology
BBSRB, Room 447
859.257.6456
TitlebPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse.
Publication TypeJournal Article
Year of Publication2011
JournalBritish journal of pharmacology
Volume163
Issue2
Pagination346-57
ISSN0007-1188
Abstract

Nicotinic acetylcholine receptors (nAChRs) containing α6β2 subunits expressed by dopamine neurons regulate nicotine-evoked dopamine release. Previous results show that the α6β2* nAChR antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB) inhibits nicotine-evoked dopamine release from dorsal striatum and decreases nicotine self-administration in rats. However, overt toxicity emerged with repeated bPiDDB treatment. The current study evaluated the preclinical pharmacology of a bPiDDB analogue.

URLhttp://dx.doi.org/10.1111/j.1476-5381.2011.01220.x
DOI10.1111/j.1476-5381.2011.01220.x
Short TitleBr J Pharmacol
X
Enter your linkblue username.
Enter your linkblue password.
Secure Login

This login is SSL protected

Loading